FDA Clearance Tracker · P170034-S005
Hydrus Microsent
Last checked: Nov 20, 2026Latest source record: Jun 4, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jun 4, 2021
Approved
Time to decision
179 days
Received Dec 7, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170034-S005
- Device name
- Hydrus Microsent
- Applicant
- Alcon Research, LLC
- Applicant location
- Fort Worth, TX
- Received
- Dec 7, 2020
- Decided
- Jun 4, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P170034
Device type
- Device type
- Intraocular pressure lowering implant (OGO)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for modified labeling that reflects the findings of the Post-Approval Study (PAS) designated as Continuation of Premarket Cohort PAS.
Source documents
Other decisions for Alcon Research, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P230012 · Decided Aug 26, 2024 · 524 days after receipt
Device type: Gases used within eye to place pressure on detached retina (LPO) · Ophthalmology
P220030 · Decided Jul 2, 2024 · 564 days after receipt
Device type: Gases used within eye to place pressure on detached retina (LPO) · Ophthalmology
- LEGION System510(k)
K191650 · Decided Nov 1, 2019 · 134 days after receipt
Device type: Unit, Phacofragmentation (HQC) · Ophthalmology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.